SavedAdd your journal

Journals / Cukurova Medical Journal / 2019 / Cilt: 44 - Sayı: 2

Chromosomal aberrations in multiple myeloma: clinical outcome and response to bortezomib

Multiple myelom’da kromozomal aberasyonlar: klinik sonuçlar ve bortezomib’ e yanıt

Semra Paydaş
Arbil Açıkalın
Emine Kılıç Bağır
Perihan Alsancak
Pages
395–401
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

With respect to chromosomal aberrations,response rates were higher in Bortezomib based therapygroup (63.2%) than conventional chemotherapy group(50%) in del (17p13) positive patients as well as in del(13q14) positive patients (61.5% in Bortezomib based,50% in conventional chemotherapy group).Conclusion: Bortezomib-containing regimens may havebeneficial effects on the clinical outcome of patients withdel (17p13) and del (13q14).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: Multiple myeloma is a heterogeneous disease,for which an understanding of the prognostic andpredictive value of chromosomal aberrations is necessaryto prescribe the most appropriate therapy.
📊
Key Findings & Data:We aimed todocument the frequencies of chromosomal aberrations inour institute and searched the relationships betweentherapy regimens and chromosomal aberrations.Materials and Methods: We analyzed the frequency ofdel(17p13), del(13q14), t(11;14), and t(4;14) in patients withMM by interphase-fluorescent in situ hybridization whowere diagnosed between January 2010 and December 2015in our institute.
💡
Conclusion & Impact:With respect to chromosomal aberrations,response rates were higher in Bortezomib based therapygroup (63.2%) than conventional chemotherapy group(50%) in del (17p13) positive patients as well as in del(13q14) positive patients (61.5% in Bortezomib based,50% in conventional chemotherapy group).Conclusion: Bortezomib-containing regimens may havebeneficial effects on the clinical outcome of patients withdel (17p13) and del (13q14).
🔬Design:Research Article
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Abstract

Purpose: Multiple myeloma is a heterogeneous disease,for which an understanding of the prognostic andpredictive value of chromosomal aberrations is necessaryto prescribe the most appropriate therapy. We aimed todocument the frequencies of chromosomal aberrations inour institute and searched the relationships betweentherapy regimens and chromosomal aberrations.Materials and Methods: We analyzed the frequency ofdel(17p13), del(13q14), t(11;14), and t(4;14) in patients withMM by interphase-fluorescent in situ hybridization whowere diagnosed between January 2010 and December 2015in our institute. We researched the relationship betweenresponse to conventional chemotherapy and Bortezomibbased chemotherapy.Results: Eighty patients (72.7%) had at least onechromosomal aberration. The most frequently observedaberration was del(17p13) (48.2%), followed by del(13q14)(40.9%), t(11;14) (16.4%), and t(4;14) (11.8%). In clinicallyanalyzed subgroup (n=67), 36 patients who receivedBortezomib based chemotherapy showed a higherresponse rate (55.6%) than conventional chemotherapygroup (48.4%). With respect to chromosomal aberrations,response rates were higher in Bortezomib based therapygroup (63.2%) than conventional chemotherapy group(50%) in del (17p13) positive patients as well as in del(13q14) positive patients (61.5% in Bortezomib based,50% in conventional chemotherapy group).Conclusion: Bortezomib-containing regimens may havebeneficial effects on the clinical outcome of patients withdel (17p13) and del (13q14).

Özet

Amaç: Mutltiple myelom heterojen bir hastalık olup, en etkin tedavinin planlanlanabilmesi için kromozomal aberasyonların prognostik ve prediktif değerlerinin anlaşılması önemlidir. Bu çalışmada kurumumuzda tanı almış hastaların kromozomal aberasyonlarının sıklığını ve tedavi seçenekleri ile arasındaki ilişkiyi araştırmayı amaçladık. Gereç ve Yöntem: Ocak 2010 ve Aralık 2015 tarihleri arasında kurumumuzda tanı almış multiple myelomlu hastalarda, interfaz-floresan in situ hibridizasyon yöntemi ile del(17p13), del(13q14), t(11;14), and t(4;14) kromozomal aberasyonlarının sıklığını araştırdık. Bu sonuçların, konvansiyonel kemoterapi alan hastalar ile bortezomib tabanlı kemoterapi alan hastalardaki yanıtlarını karşılaştırdık. Bulgular: Seksen hastada (%72.7) en az bir adet kromozomal aberasyon saptandı. En sık saptanan aberasyon del(17p13) (%48.2) idi. Bunu sırasıyla del(13q14) (%40.9), t(11;14) (%16.4), ve t(4;14) (%11.8) takip etmekteydi. Klinik bulgularına ulaşılabilen 67 hastalık grupta, Bortezomib tabanlı kemoterapi alan 36 hastanın tedaviye yanıt oranı (%55.6) konvansiyonel kemoterapi alan gruba oranla (%48.4) daha yüksek idi. Kromozomal aberasyonlar ile karşılaştırıldığında; del (17p13) saptanan hastaların Bortezomib tabanlı kemoterapiye yanıtları (%63.2), konvansiyonel kemoterapi alanlardan (%50) daha yüksek saptandı. Benzer şonuç; del (13q14) saptanan hastalarda da gözlendi (Bortezomib alanlarda %61.5, konvansiyonel kemoterapi alanlarda %50). Sonuç: Bortezomib içeren tedaviler özellikle del (17p13) ve del (13q14) aberasyonu saptanan hastalarda daha iyi sonuç vermektedir.

🔖

Cite This Article

Paydaş, S., Açıkalın, A., Bağır, E. K., Alsancak, P. (2022). Chromosomal aberrations in multiple myeloma: clinical outcome and response to bortezomib. Cukurova Medical Journal, Cilt: 44 - Sayı: 2, 395–401. https://ajindex.com/articles/476809

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. McKenna RW, Kyle RA, Kuehl WM, Harris NL, Coupland RW, Fend F. Plasma cell neoplasms. In texbook of WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Eds Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al). France: IARC press. 2017
  2. Gmidene A, Avet-Loiseau H, Sennana H, Ben Abdallah I, Khlif A, Meddeb B et al. Molecular cytogenetic aberrations in Tunisian patients with multiple myeloma identified by cIg-FISH in fixed bone marrow cells. Cytogenet Genome Res. 2012;136:44-9
  3. Gao X, Li C, Zhang R, Yang R, Qu X, Qiu H, et al.Fluorescence in situ hybridization analysis of chromosome aberrations in 60 Chinese patients with multiple myeloma. Med Oncol. 2012; 29:2200-6
  4. Seidl S, Kaufmann H, Drach J.New insights into the pathophysiology of multiple myeloma. Lancet Oncology. 2003;4:557-64
  5. Avet-Loiseau H, Malard F, Campion L, Magrangeas F, Sebban C, Lioure B, et al. Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood. 2011;117:2009-11
  6. Soverini S, Cavo M, Cellini C, Terragna C, Zamagni E, Ruggeri D et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood. 2003;102:1588-94
  7. Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Litzow MR, Henderson KJ et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood. 2005;106:2837-40
  8. Segges P, Braggio E. Genetic markers used for risk stratification in multiple myeloma. Genet Res Int. 2011;798089
  9. Terpos E, Eleutherakis-Papaiakovou V, Dimopoulos MA. Clinical implications of chromosomal abnormalities in multiple myeloma. Leukemia & Lymphoma. 2006;47:803-14
  10. Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood. 2002;100:1579-83
  11. Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood. 2003;101:1520-9
  12. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23:2210- 21
  13. Hu Y, C